An interventional study of Lorlatinib in ALK+ Non-Small-Cell Lung Carcinoma, sponsored by Pfizer. Recruiting at 32 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Pfizer · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung — 8 open to participants now, 16 under way, 1 of them phase 3. lorlatinib · Carcinoma, Non-Small-Cell Lung.
Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by planned enrollment, is one of 2 that started in 2025, is the only one with no phase, reaches primary completion later than 12 of the 15 other live ones, and was the 22nd registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →8 of the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung are open now, in 5 countries. Recruiting first, the newest first:
Chugai Pharmaceutical · Sites in United States, Japan
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Centro di Riferimento Oncologico - Aviano · Sites in Italy
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
Guangdong Association of Clinical Trials · Sites in China
Ages 18+
By country, each count listing its studies:
lorlatinib: first FDA approval 2018 (LORBRENA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 1 · Phase 4 3
First in 2014; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 45 across the 27 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 27 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer: 15 open now, 26 under way, 5 of them phase 3. Of 123 finished, 70 (57%) have results posted.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 64th largest by planned enrollment of the 136 interventional ones that give a count, is one of 8 that started in 2025, is one of 3 with no phase, reaches primary completion later than 18 of the 25 other live ones, and was the 140th registered.
Pfizer’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
1 of the studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07083687Hunan Cancer HospitalLorlatinib in ROS1+ NSCLC With Brain Metastasis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing lorlatinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 158 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World context
Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply:
Exclusion Criteria: Participants are excluded from the study if any of the following criteria Apply
Patients using any of the following food or drugs within 12 days prior to the first dose of lorlatinib:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lorlatinib single agent, 100 mg (4 x 25 mg) oral tables, QD, continuously
Drug: Lorlatinib
ALK-positive NSCL treatment
Also known as: PF-06463922
Progression-Free Survival (PFS)
Time from inclusion to date of disease progression or death of any cause whichever occurs first.
Time frame: From time of Study Start up to 25 months
Overall Survival (OS)
Time from inclusion to date of death from any cause.
Time frame: From time of Study Start up to 25 months
Objective Response Rate (ORR)
proportion of patients with a Complete Response (CR) or Partial Response (PR) as a best response during the lorlatinib treatment. Responses to treatment will be defined according to investigator
Time frame: From time of Study Start up to 24 months
Duration of Response (DR)
time between the first documentation of objective response and the first documentation of disease progression or death from any cause whichever occurred first, for participants with a confirmed objective response of CR or PR.
Time frame: From time of Study Start up to 24 months
Intracranial Objective Response Rate (IC-ORR)
proportion of patients with intracranial objective response of complete response (CR) or partial response (PR) as a best response in the subset of patients with at least 1 intracranial lesion assessed by investigator.
Time frame: From time of Study Start up to 24 months
Intracranial Time to Progression (IC-TTP)
Time from inclusion to the date of the first documentation of disease progression of intracranial disease, based on either new brain metastases or progression of existing brain metastases.
Time frame: From time of Study Start up to 24 months
Intracranial Duration of Response (IC-DR)
time from the first documentation of intracranial OR to the first documentation of intracranial progressive disease (PD) or death due to any cause, whichever occurred first for participants with a confirmed objective response of CR or PR assessed by investigator.
Time frame: From time of Study Start up to 24 months
Duration of Treatment (DT)
Time between inclusion and last dose of lorlatinib.
Time frame: From time of Study Start up to 25 months
Proportion of patients with extracranial progression and sites of progression
Based on Investigator's Assessment
Time frame: From time of Study Start up to 24 months
Time to Treatment Failure (TTF)
Time from date of treatment initiation to date of discontinuation of treatment for any reason, including progression of disease, treatment toxicity, and death from any cause whichever occurs first.
Time frame: From time of Study Start up to 24 months
Adverse Event (AE) as graded by NCI CTCAE v5)
Frequency of patients experiencing treatment-emergent AEs (TEAEs)
Time frame: From time of Study Start up to 25 months
Number of Participants With Treatment-Emergent Adverse Events (AEs; Treatment-Related
Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. Treatment-related AEs were determined by investigators.
Time frame: From time of Study Start up to 25 months
Proportion of patients considered observant to treatment assessed by the compliance questionnaire.
Self-administered questionnaire that provides a measure of compliance
Time frame: At the start of cycle (each cyle is 28 days) Cycle2Day1, Cycle3Day1, Cycle4Day1 and then every 3 months - as long as 48 months
Proportion of patients experiencing a 10-points change from baseline in total score for the EORTC QLQ-C30
evaluate Health-related Quality of life (HRQoL) of ALK- positive locally advanced or metastatic NSCLC patients treated with lorlatinib in first-line using the EORTC QLQ-C30 questionnaires
Time frame: At inclusion, At the start of Cycle (each cycle is 28 days) Cycle2Day1, Cycle3Day1, Cycle4Day1 and every 3 months until the first year and then every 6 months - as long as 48 months
Proportion of patients experiencing a 10-points change from baseline in total score for the EORT QLQ-LC13.
Evaluate Health-related Quality of life (HRQoL) of ALK- positive locally advanced or metastatic NSCLC patients treated with lorlatinib in first-line using the EORTC QLQ -LC13 questionnaires
Time frame: At inclusion, At the start of Cycle (each cycle is 28 days) Cycle2Day1, Cycle3Day1, Cycle4Day1 and every 3 months until the first year and then every 6 months - as long as 48 months
Patient Reported Outcome-informed CNS symptomatic toxicity:
frequency, severity and/or interference with daily activities, amount, presence/absence according to PRO-CTCAE questionnaires for mood (anxious/discouraged/sad), and attention/memory items (concentration/memory).
Time frame: At inclusion, At the start of cycle (each cycle is 28 days) Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle4Day1 and every 3 months until the first year and then every 6 months - as long as 48 months
Proportion of patients experiencing grade III toxicities or progression and having an over- or under-exposure to lorlatinib.
At each time point, a blood sample to provide plasma for determination of the plasma concentrations of lorlatinib.
Time frame: At baseline, at start of Cycle1Day15 (each cycle is 28 days), Month 3, Month 9 and every 6 months through the end of treatment, at time of first grade III of hyperlipidaemia and CNS toxicity onset, and at progression - as long as 48 months
Proportion of patients experiencing each kind of identified lorlatinib resistance mechanisms
Plasma samples collected at baseline and end of treatment, analyzed by next-generation sequencing
Time frame: At baseline and at the date of first documented progression (as long as 48 months)
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Started Jan 2025 (actual). Primary completion is estimated for Nov 2028, 46 months after the start.
Of 360 interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 97. This study's planned 46 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorlatinib
Carcinoma, Non-Small-Cell Lung →